Table 3.
Immunogenicity rate (ITT population)*
| Antiabatacept | Anti–CTLA-4-T | Total | |
|---|---|---|---|
| SC | |||
| Treatment visit | 3/707 (0.4) | 2/716 (0.3) | 5/716 (0.7) |
| Posttreatment visit† | 0/26 | 3/28 (10.7) | 3/28 (10.7) |
| Overall | 3/714 (0.4) | 5/725 (0.7) | 8/725 (1.1) |
| IV | |||
| Treatment visit | 5/691 (0.7) | 4/702 (0.6) | 9/702 (1.3) |
| Posttreatment visit† | 0/29 | 7/31 (22.6) | 7/31 (22.6) |
| Overall | 5/698 (0.7) | 11/710 (1.5) | 16/710 (2.3) |
*
Values are the number/total number (%) of patients. Data are based on patients for whom immunogenicity assessments were available. Anti–CTLA-4-T = anti–cytotoxic T lymphocyte–associated protein 4 Tip (see Table 1 for other definitions).
†
Assessed for up to 85 days after withdrawal from the study.